Valuation: Altimmune Inc

Market Cap 552M 486M 451M 415M 778M 53.49B 792M 5.4B 2.1B 26.09B 2.07B 2.03B 90.51B P/E 2026 *
-4.22x
P/E 2027 * -3.75x
Enterprise Value 108M 94.82M 88.08M 81.01M 152M 10.44B 155M 1.05B 411M 5.09B 405M 396M 17.67B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.59%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 58 2025-12-31
Director of Finance/CFO 70 2024-11-10
Chief Tech/Sci/R&D Officer - 2025-04-30
Director TitleAgeSince
Director/Board Member 58 2003-08-31
Chairman 78 2017-12-31
Director/Board Member 76 2012-06-30
Change 5-day change 1-year change 3-year change Capi.($)
-10.28%-43.79% - - 552M
-1.92%-1.57%+48.70%+84.37% 55.92B
+0.93%+6.97%+62.83%+67.97% 56.67B
-2.16%-1.46%-21.32%-15.78% 23.28B
-0.88%-1.51%+3.05%+421.41% 23.28B
-0.36%-0.56%+36.00%-3.93% 20.54B
-1.34%+0.51%+25.02%-30.27% 17.78B
-1.44%-1.63%+37.07%+589.93% 15.9B
-1.30%-9.92%+160.67%+284.37% 14.64B
+0.03%-0.23%+24.56%+180.49% 13.99B
Average -1.88%+0.47%+41.84%+175.39% 26.89B
Weighted average by Cap. -0.84%+1.47%+42.68%+138.27%

Financials

2026 *2027 *
Net sales - -
Net income -108M -94.58M -87.87M -80.81M -152M -10.41B -154M -1.05B -410M -5.08B -404M -395M -17.62B -131M -116M -107M -98.78M -185M -12.73B -189M -1.28B -501M -6.21B -494M -483M -21.54B
Net Debt -444M -391M -363M -334M -626M -43.05B -638M -4.34B -1.69B -21B -1.67B -1.63B -72.84B -340M -299M -278M -255M -479M -32.91B -487M -3.32B -1.29B -16.05B -1.28B -1.25B -55.68B
Logo Altimmune Inc
Altimmune, Inc. is a late clinical-stage biopharmaceutical company. The Company is developing novel therapies for serious liver diseases. Its lead product candidate, pemvidutide (formerly ALT-801), is a balanced 1:1 glucagon/GLP-1 dual receptor agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). The activation of glucagon receptors results in direct effects on the liver, including reductions in liver fat, inflammation and fibrosis, whereas the activation of GLP-1 receptors mediates suppression of appetite and reduction of cravings as well as metabolic effects such as weight loss. It has completed phase II development of pemvidutide. It also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-